<p>Fortem Financial Group LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Cencora, Inc. (NYSE:COR - 免费报告) 的持股减少了 76.1%。该公司在季度内出售了 5,917 股后，持有 1,858 股 Cencora 的股票。Fortem Financial Group LLC 在 Cencora 的持股在最近的报告期末价值为 628,000 美元。</p>
<ul>
<li>主动型 ETF 超越被动型，领先者为这些</li>
</ul>
<p>其他几家对冲基金和机构投资者也对其在 COR 的持仓进行了调整。联合银行在第二季度将其在 Cencora 的持股提高了 4.5%。联合银行现在拥有 7,032 股该公司的股票，价值 2,109,000 美元，此前在上个季度又增持了 305 股。Nebula Research &amp; Development LLC 在第二季度购买了 Cencora 的新头寸，价值约为 595,000 美元。北卡罗来纳州财政部长在第二季度将其在 Cencora 的持股提高了 7.9%。北卡罗来纳州财政部长现在拥有 85,534 股该公司的股票，价值 25,647,000 美元，此前在上个季度又增持了 6,244 股。Diversify Advisory Services LLC 在第二季度将其在 Cencora 的持股提高了 94.1%。Diversify Advisory Services LLC 现在拥有 2,585 股该公司的股票，价值 747,000 美元，此前在上个季度又增持了 1,253 股。最后，DZ BANK AG 德意志中央合作银行法兰克福在第二季度将其在 Cencora 的持股提高了 26.0%。DZ BANK AG 德意志中央合作银行法兰克福现在拥有 73,452 股该公司的股票，价值 22,025,000 美元，此前在上个季度又增持了 15,154 股。对冲基金和其他机构投资者持有该公司 97.52% 的股票。</p>
<h2>Cencora 股票表现</h2>
<p>COR 的股票在周一开盘价为 261.16 美元。该公司的债务与股本比率为 3.40，速动比率为 0.59，流动比率为 0.95。该股票的市值为 508 亿美元，市盈率为 20.03，市盈率/增长比率为 1.21，贝塔值为 0.64。Cencora, Inc. 的 50 日移动平均线为 327.81 美元，200 日移动平均线为 342.26 美元。Cencora, Inc. 的一年低点为 244.82 美元，一年高点为 377.54 美元。</p>
<ul>
<li>在下跌市场中，标普 500 的前三大赢家</li>
</ul>
<p>Cencora (NYSE:COR - 获取免费报告) 最近在 5 月 6 日星期三发布了其财报。该公司报告季度每股收益为 4.75 美元，低于市场共识预期的 4.82 美元，差额为 0.07 美元。该季度的收入为 783.6 亿美元，而分析师预期为 810.9 亿美元。Cencora 的股本回报率为 135.20%，净利润率为 0.78%。Cencora 的季度收入同比增长 3.9%。在去年同期，该公司每股收益为 4.42 美元。Cencora 已将其 2026 财年的每股收益指引设定为 17.650-17.900 美元。平均而言，卖方分析师预测 Cencora, Inc. 今年的每股收益将为 17.73 美元。</p>
<h2>Cencora 分红公告</h2>
<p>该公司最近还披露了一项季度分红，将于 6 月 1 日星期一支付。5 月 15 日星期五的登记投资者将获得 0.60 美元的分红。除息日为 5 月 15 日星期五。这代表着每年 2.40 美元的分红和 0.9% 的分红收益率。Cencora 当前的派息比率为 18.40%。</p>
<h2>影响 Cencora 的关键头条</h2>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
<p>以下是本周影响 Cencora 的关键新闻：</p>
<ul>
<li>积极情绪：Cencora 将 2026 财年的每股收益指引提高至 17.65-17.90 美元，并恢复了 10 亿美元的股票回购计划，显示管理层对盈利能力和资本回报的信心。</li>
<li>积极情绪：尽管下调了目标价，但包括花旗和贝尔德在内的几家华尔街公司仍维持看涨评级，表明分析师仍然看到上涨空间，尽管市场出现抛售。</li>
<li>中性情绪：关于该股票的评论强调了 “估值辩论”，以及收益后下跌是否过度，表明投资者正在重新评估预期，而不是对新的运营冲击做出反应。Cencora NYSE 综合重置引发估值辩论</li>
<li>中性情绪：分析师和媒体的报道也集中在利润率扩张与增长之间的辩论，反映出 Cencora 是否优先考虑盈利能力和回购而非收入增长的争论。Cencora (COR) 是否在提高每股收益展望和回购中优先考虑利润率扩张而非增长？</li>
<li>消极情绪：主要的看空驱动因素是财报，未能达到每股收益预期，且销售额低于分析师预期，引发对近期增长势头的担忧。Cencora NYSE: COR 在 2026 财年第一季度的销售额低于分析师预期</li>
<li>消极情绪：证券欺诈调查公告可能增加负担和法律风险担忧，可能在更多细节明确之前恶化情绪。对 Cencora, Inc. (COR) 的证券欺诈调查已宣布。</li>
</ul>
<h2>分析师设定新目标价</h2>
<p>COR 已成为多份研究分析师报告的主题。瑞银集团在周四的报告中将 Cencora 的目标股价从 410.00 美元上调至 412.00 美元，并给予该股票 &#34;买入&#34; 评级。摩根大通在 2 月 10 日（周二）的报告中将 Cencora 的目标股价从 417.00 美元上调至 419.00 美元，并给予公司 &#34;增持&#34; 评级。Leerink Partners 在 3 月 17 日（周二）的报告中重申了对 Cencora 的 &#34;跑赢大盘&#34; 评级。摩根士丹利在周五的报告中设定了 Cencora 的目标股价为 342.00 美元。最后，杰富瑞金融集团在 1 月 22 日（周四）的报告中将 Cencora 的评级从 &#34;表现不佳&#34; 上调至 &#34;买入&#34;。共有十二位分析师给予该股票 &#34;买入&#34; 评级，三位分析师给予公司 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标股价为 388.42 美元。</p>
<p><strong>查看我们关于 Cencora 的最新股票报告</strong></p>
<h2>关于 Cencora</h2>
<p>(免费报告)</p>
<p>Cencora（纽约证券交易所代码：COR）是一家全球医疗服务和制药分销公司，提供覆盖制药供应链的端到端解决方案。公司的核心业务包括批发药品分销、特殊药品分销以及特殊药房的运营，辅以物流、冷链管理和其他旨在支持复杂和温度敏感疗法的履行服务。</p>
<p>除了实体分销，Cencora 还为制药制造商和医疗服务提供者提供一系列商业和以患者为中心的服务。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Cencora</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗股票将从一项重大法案中受益</li>
</ul>
<p><strong>想看看其他对 COR 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得 &#34;适度买入&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

制药 ETF - VanEck Vectors

美国制药 ETF - iShares

动态制药业投资组合 ETF - Invesco

标普制药指数 ETF - SPDR

<p>Fortem Financial Group LLC 在第四季度减少了对 Cencora, Inc. (NYSE:COR) 的持股，减幅为 76.1%，目前持有 1,858 股，之前出售了 5,917 股。其他机构投资者也调整了他们的持仓，United Bank 增加了 4.5% 的股份。Cencora 的股票开盘价为 261.16 美元，市值为 508 亿美元。该公司报告第一季度每股收益为 4.75 美元，未达到预期，并将 2026 财年的每股收益指引上调至 17.65-17.90 美元。Cencora 还宣布季度股息为 0.60 美元，反映出 0.9% 的收益率</p>

<p>Fortem Financial Group LLC decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 76.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,858 shares of the company's stock after selling 5,917 shares during the quarter. Fortem Financial Group LLC's holdings in Cencora were worth $628,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Fortem Financial Group LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Cencora, Inc. (NYSE:COR - 免费报告) 的持股减少了 76.1%。该公司在季度内出售了 5,917 股后，持有 1,858 股 Cencora 的股票。Fortem Financial Group LLC 在 Cencora 的持股在最近的报告期末价值为 628,000 美元。</p>
</div><ul>
<li>Active ETFs Surge Past Passive, and These Are in the Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>主动型 ETF 超越被动型，领先者为这些</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also made changes to their positions in COR. United Bank lifted its stake in Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company's stock worth $2,109,000 after acquiring an additional 305 shares during the last quarter. Nebula Research &amp; Development LLC purchased a new position in Cencora in the second quarter worth approximately $595,000. Treasurer of the State of North Carolina raised its holdings in Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company's stock worth $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC raised its holdings in Cencora by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company's stock worth $747,000 after purchasing an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Cencora by 26.0% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company's stock worth $22,025,000 after purchasing an additional 15,154 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者也对其在 COR 的持仓进行了调整。联合银行在第二季度将其在 Cencora 的持股提高了 4.5%。联合银行现在拥有 7,032 股该公司的股票，价值 2,109,000 美元，此前在上个季度又增持了 305 股。Nebula Research &amp; Development LLC 在第二季度购买了 Cencora 的新头寸，价值约为 595,000 美元。北卡罗来纳州财政部长在第二季度将其在 Cencora 的持股提高了 7.9%。北卡罗来纳州财政部长现在拥有 85,534 股该公司的股票，价值 25,647,000 美元，此前在上个季度又增持了 6,244 股。Diversify Advisory Services LLC 在第二季度将其在 Cencora 的持股提高了 94.1%。Diversify Advisory Services LLC 现在拥有 2,585 股该公司的股票，价值 747,000 美元，此前在上个季度又增持了 1,253 股。最后，DZ BANK AG 德意志中央合作银行法兰克福在第二季度将其在 Cencora 的持股提高了 26.0%。DZ BANK AG 德意志中央合作银行法兰克福现在拥有 73,452 股该公司的股票，价值 22,025,000 美元，此前在上个季度又增持了 15,154 股。对冲基金和其他机构投资者持有该公司 97.52% 的股票。</p>
</div><h2>Cencora Stock Performance</h2>
<div class="lb-trans"><h2>Cencora 股票表现</h2>
</div><p>Shares of COR opened at $261.16 on Monday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market capitalization of $50.80 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.21 and a beta of 0.64. The company's fifty day moving average is $327.81 and its two-hundred day moving average is $342.26. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.</p>
<div class="lb-trans"><p>COR 的股票在周一开盘价为 261.16 美元。该公司的债务与股本比率为 3.40，速动比率为 0.59，流动比率为 0.95。该股票的市值为 508 亿美元，市盈率为 20.03，市盈率/增长比率为 1.21，贝塔值为 0.64。Cencora, Inc. 的 50 日移动平均线为 327.81 美元，200 日移动平均线为 342.26 美元。Cencora, Inc. 的一年低点为 244.82 美元，一年高点为 377.54 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标普 500 的前三大赢家</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts' expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora's revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 17.73 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cencora (NYSE:COR - 获取免费报告) 最近在 5 月 6 日星期三发布了其财报。该公司报告季度每股收益为 4.75 美元，低于市场共识预期的 4.82 美元，差额为 0.07 美元。该季度的收入为 783.6 亿美元，而分析师预期为 810.9 亿美元。Cencora 的股本回报率为 135.20%，净利润率为 0.78%。Cencora 的季度收入同比增长 3.9%。在去年同期，该公司每股收益为 4.42 美元。Cencora 已将其 2026 财年的每股收益指引设定为 17.650-17.900 美元。平均而言，卖方分析师预测 Cencora, Inc. 今年的每股收益将为 17.73 美元。</p>
</div><h2>Cencora Dividend Announcement</h2>
<div class="lb-trans"><h2>Cencora 分红公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora's payout ratio is currently 18.40%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 6 月 1 日星期一支付。5 月 15 日星期五的登记投资者将获得 0.60 美元的分红。除息日为 5 月 15 日星期五。这代表着每年 2.40 美元的分红和 0.9% 的分红收益率。Cencora 当前的派息比率为 18.40%。</p>
</div><h2>Key Headlines Impacting Cencora</h2>
<div class="lb-trans"><h2>影响 Cencora 的关键头条</h2>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
</div><p>Here are the key news stories impacting Cencora this week:</p>
<div class="lb-trans"><p>以下是本周影响 Cencora 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.</li>
<li>Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.</li>
<li>Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate</li>
<li>Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?</li>
<li>Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora NYSE: COR reports sales below analyst estimates in Q1 CY2026 earnings</li>
<li>Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Cencora 将 2026 财年的每股收益指引提高至 17.65-17.90 美元，并恢复了 10 亿美元的股票回购计划，显示管理层对盈利能力和资本回报的信心。</li>
<li>积极情绪：尽管下调了目标价，但包括花旗和贝尔德在内的几家华尔街公司仍维持看涨评级，表明分析师仍然看到上涨空间，尽管市场出现抛售。</li>
<li>中性情绪：关于该股票的评论强调了 “估值辩论”，以及收益后下跌是否过度，表明投资者正在重新评估预期，而不是对新的运营冲击做出反应。Cencora NYSE 综合重置引发估值辩论</li>
<li>中性情绪：分析师和媒体的报道也集中在利润率扩张与增长之间的辩论，反映出 Cencora 是否优先考虑盈利能力和回购而非收入增长的争论。Cencora (COR) 是否在提高每股收益展望和回购中优先考虑利润率扩张而非增长？</li>
<li>消极情绪：主要的看空驱动因素是财报，未能达到每股收益预期，且销售额低于分析师预期，引发对近期增长势头的担忧。Cencora NYSE: COR 在 2026 财年第一季度的销售额低于分析师预期</li>
<li>消极情绪：证券欺诈调查公告可能增加负担和法律风险担忧，可能在更多细节明确之前恶化情绪。对 Cencora, Inc. (COR) 的证券欺诈调查已宣布。</li>
</ul>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>COR has been the topic of a number of research analyst reports. UBS Group raised their price objective on shares of Cencora from $410.00 to $412.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. JPMorgan Chase &amp; Co. lifted their target price on shares of Cencora from $417.00 to $419.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, February 10th. Leerink Partners reaffirmed an &#34;outperform&#34; rating on shares of Cencora in a report on Tuesday, March 17th. Morgan Stanley set a $342.00 target price on shares of Cencora in a report on Friday. Finally, Jefferies Financial Group raised shares of Cencora from an &#34;underperform&#34; rating to a &#34;buy&#34; rating in a report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $388.42.</p>
<div class="lb-trans"><p>COR 已成为多份研究分析师报告的主题。瑞银集团在周四的报告中将 Cencora 的目标股价从 410.00 美元上调至 412.00 美元，并给予该股票 &#34;买入&#34; 评级。摩根大通在 2 月 10 日（周二）的报告中将 Cencora 的目标股价从 417.00 美元上调至 419.00 美元，并给予公司 &#34;增持&#34; 评级。Leerink Partners 在 3 月 17 日（周二）的报告中重申了对 Cencora 的 &#34;跑赢大盘&#34; 评级。摩根士丹利在周五的报告中设定了 Cencora 的目标股价为 342.00 美元。最后，杰富瑞金融集团在 1 月 22 日（周四）的报告中将 Cencora 的评级从 &#34;表现不佳&#34; 上调至 &#34;买入&#34;。共有十二位分析师给予该股票 &#34;买入&#34; 评级，三位分析师给予公司 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标股价为 388.42 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cencora 的最新股票报告</strong></p>
</div><h2>About Cencora</h2>
<div class="lb-trans"><h2>关于 Cencora</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR）是一家全球医疗服务和制药分销公司，提供覆盖制药供应链的端到端解决方案。公司的核心业务包括批发药品分销、特殊药品分销以及特殊药房的运营，辅以物流、冷链管理和其他旨在支持复杂和温度敏感疗法的履行服务。</p>
</div><p>Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.</p>
<div class="lb-trans"><p>除了实体分销，Cencora 还为制药制造商和医疗服务提供者提供一系列商业和以患者为中心的服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Cencora</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗股票将从一项重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding COR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 COR 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得 &#34;适度买入&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fortem Financial Group LLC Lowers Holdings in Cencora, Inc. $COR

Market Beat

Cencora

联合银行

沃尔格林联合博姿

花旗

Baird Medical Investment

标普 500 指数

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Fortem Financial Group LLC 减少了其在 Cencora, Inc. $COR 的持股量